Skip to main content
Clinical Trials/NCT00790062
NCT00790062
Completed
Phase 4

Comparison of the Effectiveness of 3 Different Dose Regimens of Oxytocin in Preventing Uterine Atony and Postpartum Hemorrhage During Vaginal Delivery

University of Alabama at Birmingham1 site in 1 country1,798 target enrollmentNovember 2008

Overview

Phase
Phase 4
Intervention
Oxytocin
Conditions
Uterine Atony
Sponsor
University of Alabama at Birmingham
Enrollment
1798
Locations
1
Primary Endpoint
Women in Each Group With Risk Factors for Atony or Postpartum Hemorrhage
Status
Completed
Last Updated
10 years ago

Overview

Brief Summary

This is a double-blind 3-arm randomized clinical trial to determine whether higher dose oxytocin regimens (compared to the standard regimen) reduce the frequency of uterine atony and postpartum hemorrhage after vaginal delivery. Uterine atony is a loss of tone in the uterine musculature which can cause acute postpartum hemorrhage, which is the major cause of maternal mortality worldwide. Oxytocin is routinely administered postpartum in the US and effectively reduces uterine atony. The optimal dose of oxytocin for vaginal delivery is not known.

Detailed Description

Same as brief summary. Prospective interim monitoring (stopping) rules will be assessed upon recruitment of 2/3rds of the sample size of 1800. Interim review was conducted by a 3-member DSMB in January of 2010 and their recommendations were implemented.

Registry
clinicaltrials.gov
Start Date
November 2008
End Date
June 2010
Last Updated
10 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Alan Tita

Associate Professor

University of Alabama at Birmingham

Eligibility Criteria

Inclusion Criteria

  • \> 24 weeks, viable pregnancy, singleton or twins

Exclusion Criteria

  • No consent
  • Contraindication to oxytocin
  • Antepartum fetal demise
  • Intrapartum use of concentrated oxytocin
  • Planned cesarean
  • DIC or coagulopathy

Arms & Interventions

Oxytocin 10 units/500cc

1 dose only for prophylaxis given over 1 hour

Intervention: Oxytocin

Oxytocin 40 units/500cc

One dose only given over 1 hour. Per DSMB recommendations, this intermediate arm was stopped Jan 2010.

Intervention: Oxytocin

Oxytocin 80U/500cc

1 dose only given over 1 hour

Intervention: Oxytocin

Outcomes

Primary Outcomes

Women in Each Group With Risk Factors for Atony or Postpartum Hemorrhage

Time Frame: Initial hospital discharge (2-3 days)

In a secondary data analysis, a parsimonious set of independent risk factors for atony or postpartum hemorrhage was established: White, Hispanic, or Other (non-Black of African American) race/ethnicity, preeclampsia, or chorioamnionitus.

Number of Subjects Reporting Uterine Atony or Postpartum Hemorrhage Requiring Medical (Medication or Blood Transfusion), Surgical or Other Interventional Treatment

Time Frame: baseline to discharge (2 - 3 days)

the number of subjects with any treatment of uterineatony or hemorrhage.

Risk to Using Increasing Doses of Oxytocin Based on Pre-specified Risk Factors

Time Frame: baseline to discharge (2-3 days)

The frequency of the primary study outcome is examined in a subgroup of 939 women with risk factors for atony or postpartum hemorrhage. These risk factors are identified as White, Hispanic, or Other (non-Black or African American) race/ethnicity, chorioamnionitis, and preeclampsia.

Secondary Outcomes

  • Number of Participants Experiencing Individual Treatment or Intervention in the Primary Outcome(prior to discharge)
  • Number of Subjects Requiring Hypotension Warranting Pressor Agent or Fluid Bolus(Initial hospital discharge (2-3 days or more))
  • Change in Pre- to Post-delivery Hematocrit (%)(During delivery hospitalization: Admission hematocrit - post-delivery hematocrit)
  • Number of Participants Experiencing Postpartum Hemorrhage (Clinical Estimate Greater Than 500cc)(Initial hospital discharge (2-3 days))
  • Number of Subjects With Hospital Stays Greater Than 4 Days(Initial hospital discharge (2 days or more))

Study Sites (1)

Loading locations...

Similar Trials